haloperidol has been researched along with Drug Withdrawal Symptoms in 249 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors report a case of a patient, who in a few days after an abrupt discontinuation of clozapine and haloperidol developed agitated and confused state resembling neuroleptic malignant syndrome (NMS) and clozapine withdrawal symptoms at the same time." | 7.73 | Neuroleptic malignant syndrome and clozapine withdrawal at the same time? ( Aukst-Margetić, B; Margetić, B, 2005) |
| "Increased noradrenergic activity during chronic dopamine blockade may be an episode marker and may predict relapse within 6 weeks following haloperidol withdrawal in schizophrenia." | 7.69 | Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. ( Agren, H; Gurklis, J; O'Connor, DT; Peters, JL; van Kammen, DP; Yao, JK, 1994) |
| "In the week prior to discontinuation of haloperidol treatment, global behavioral ratings and a lumbar puncture for cerebrospinal fluid monoamine metabolities were obtained in 88 patients with chronic schizophrenia." | 7.69 | Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. ( Gilbertson, MW; Gurklis, JA; Kelley, ME; Peters, JL; van Kammen, DP; Yao, JK, 1995) |
| "We describe the second reported case of neuroleptic malignant syndrome (NMS) related to tetrabenazine therapy in Huntington's disease." | 7.68 | Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. ( Giménez-Roldán, S; Mateo, D; Muñoz-Blanco, JL, 1992) |
| "Trials of novel compounds for the treatment of schizophrenia are typically tested in patients following brief withdrawal of ongoing medication despite known long-term changes in the dopamine (DA) system following chronic antipsychotic drug therapy." | 5.40 | Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. ( Cook, JM; Gill, KM; Grace, AA; Poe, MM, 2014) |
| "To more clearly clarify the efficacy of the atypical antipsychotics compared to conventional antipsychotics, we add data on the outcome of patients diagnosed with schizophrenia from two large, international clinical trials comparing olanzapine with haloperidol (n = 1996) and olanzapine with risperidone (n = 339)." | 5.10 | Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. ( Berg, PH; Glick, ID, 2002) |
| "The aim of the study was to examine effects of haloperidol on the relationships between neuropsychological measures of frontal lobe functioning and the schizophrenia syndromes of psychomotor poverty and disorganization." | 5.09 | Influence of haloperidol on the relationship of frontal lobe function to psychomotor poverty and disorganization syndromes. ( Allen, DN; Anastasiou, A; Gilbertson, M; Goldstein, G; van Kammen, DP, 2000) |
| "Intravenous haloperidol is recommended as the drug of choice to treat delirium in ICU patients." | 4.79 | Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients. ( Fraser, GL; Richen, P; Riker, RR, 1997) |
| "Lithium carbonate is the single most important long-term treatment for recurrent affective disorders." | 4.76 | Lithium. ( DePaulo, JR, 1984) |
| "The authors report a case of a patient, who in a few days after an abrupt discontinuation of clozapine and haloperidol developed agitated and confused state resembling neuroleptic malignant syndrome (NMS) and clozapine withdrawal symptoms at the same time." | 3.73 | Neuroleptic malignant syndrome and clozapine withdrawal at the same time? ( Aukst-Margetić, B; Margetić, B, 2005) |
| "Increased noradrenergic activity during chronic dopamine blockade may be an episode marker and may predict relapse within 6 weeks following haloperidol withdrawal in schizophrenia." | 3.69 | Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. ( Agren, H; Gurklis, J; O'Connor, DT; Peters, JL; van Kammen, DP; Yao, JK, 1994) |
| "In the week prior to discontinuation of haloperidol treatment, global behavioral ratings and a lumbar puncture for cerebrospinal fluid monoamine metabolities were obtained in 88 patients with chronic schizophrenia." | 3.69 | Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. ( Gilbertson, MW; Gurklis, JA; Kelley, ME; Peters, JL; van Kammen, DP; Yao, JK, 1995) |
| "The long-term effects of haloperidol on weight were assessed in 30 children, 25 males and 5 females, diagnosed with autistic disorder whose ages ranged from 3." | 3.68 | Haloperidol withdrawal and weight changes in autistic children. ( Anderson, LT; Campbell, M; Malone, RP; Shay, J; Silva, RR, 1993) |
| "Clozapine and haloperidol were tested for their ability to influence the acquisition of kindled seizures following electrical stimulation of the amygdala and ventral hippocampus." | 3.68 | Clozapine inhibits limbic system kindling: implications for antipsychotic action. ( Graham, SR; Kokkinidis, L, 1993) |
| "After cessation of long-term treatment with haloperidol, a 77-year-old man developed severe dyskinetic-dystonic movements involving mainly the tongue and associated also with oromandibular dystonia and blepharospasm that were manifested exclusively during the process of eating and that interfered with feeding." | 3.68 | Tardive eating dystonia. ( Achiron, A; Melamed, E, 1990) |
| " But 2 days later he developed auditory hallucinations which were interpreted as alcohol hallucinations, for which he was additionally given haloperidol, 15 mg/d." | 3.68 | [Central anticholinergic intoxication syndrome. A contribution to the differential diagnosis of exogenous psychoses]. ( Eikmeier, G; Gastpar, M; Kastrup, O, 1991) |
| "We describe the second reported case of neuroleptic malignant syndrome (NMS) related to tetrabenazine therapy in Huntington's disease." | 3.68 | Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. ( Giménez-Roldán, S; Mateo, D; Muñoz-Blanco, JL, 1992) |
| "The authors conducted a multicenter, double-blind, placebo-controlled, randomized trial of flexibly dosed quetiapine and haloperidol." | 2.72 | Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. ( Copenhaver, M; Katz, IR; Mintzer, JE; Schneider, L; Street, J; Tariot, PN; Williams-Hughes, C, 2006) |
| "Symptoms of the autonomic nervous system were more effectively prevented by GHB as evident in the lower dosage requirement of clonidine." | 2.69 | [Gamma-hydroxybutyrate for treatment of alcohol withdrawal syndrome in intensive care patients. A comparison between with two symptom-oriented therapeutic concepts]. ( Lenzenhuber, E; Müller, C; Rommelspacher, H; Spies, C, 1999) |
| "Haloperidol treatment masked withdrawal-exacerbated tardive dyskinesia more than molindone did; this difference (measured by percent change in AIMS scores) was significant (p = ." | 2.66 | Molindone and haloperidol in tardive dyskinesia. ( Benarroche, CL; Glazer, WM; Hafez, HM, 1985) |
| "Two patients with akathisia developing only after neuroleptic dosage reduction or withdrawal are described." | 2.39 | Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. ( Lang, AE, 1994) |
| "Lorazepam is an excellent first choice because of its intermediate half-life, absence of active metabolites, and high bioavailability that can be achieved with a number of routes of administration." | 2.37 | Emerging treatment options in the alcohol withdrawal syndrome. ( Rosenbloom, A, 1988) |
| "Treatment with carisoprodol and phenobarbital provided additional benefit and can be considered in cases of severe carisoprodol withdrawal." | 1.46 | Severe Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose. ( Benowitz, NL; Horng, H; Smollin, CG; Vo, KT, 2017) |
| "Trials of novel compounds for the treatment of schizophrenia are typically tested in patients following brief withdrawal of ongoing medication despite known long-term changes in the dopamine (DA) system following chronic antipsychotic drug therapy." | 1.40 | Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. ( Cook, JM; Gill, KM; Grace, AA; Poe, MM, 2014) |
| " In the present study, we investigated the effects of acute administration or withdrawal from long-term administration of haloperidol and/or ziprasidone on morphine-induced open-field behaviour in mice." | 1.40 | Effects of acute and long-term typical or atypical neuroleptics on morphine-induced behavioural effects in mice. ( Berro, LF; Carvalho, RC; Frussa-Filho, R; Fukushiro, DF; Hollais, AW; Kameda, SR; Patti, CL; Zanin, KA, 2014) |
| " In contrast, chronic administration of ketamine not only produced significant 'hyperactivity' response but also enhanced the immobility period in animals during the forced swim test and reduced the latency period in the passive avoidance test." | 1.37 | Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. ( Chatterjee, M; Ganguly, S; Palit, G; Srivastava, M, 2011) |
| "treated with haloperidol (1." | 1.35 | Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice. ( Alvarez, Jdo N; Carvalho, Rde C; Frussa-Filho, R; Fukushiro, DF; Ribeiro, LT; Ricardo, VP, 2008) |
| "Catalepsy was monitored on an inclined surface." | 1.35 | Dietary supplementations of amino acids: evidence for enhanced serotonergic functions following haloperidol withdrawal in rat medial prefrontal cortex. ( Ahmed, S; Batool, F; Haleem, DJ, 2009) |
| " We compared the effects of withdrawal from long-term administration of the typical neuroleptic haloperidol (Hal) and/or the atypical agent risperidone (Ris) on MDS and NDS, behaviorally evaluated by amphetamine-induced locomotor stimulation (AILS) and apomorphine-induced stereotypy (AIS) in mice, respectively." | 1.35 | Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. ( Callegaro-Filho, D; Carvalho, RC; Frussa-Filho, R; Fukushiro, DF; Helfer, DC; Sanday, L; Silva, RH; Trombin, TF; Zanlorenci, LH, 2009) |
| "treated with haloperidol (1." | 1.34 | Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. ( Alvarez, Jdo N; Chinen, CC; de Castro, JP; Frussa-Filho, R; Fukushiro, DF; Tatsu, JA, 2007) |
| " In view of a role of 5-hydroxytryptamine (5-HT; serotonin)-1A receptors in the elicitation of EPS, the present study concerns pre- and postsynaptic responses to a selective 5-HT-1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) following acute and chronic administration of haloperidol in rats." | 1.32 | Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats. ( Haleem, DJ; Khan, NH, 2003) |
| "Two cases of schizophrenia are reported in which insomnia developed after biperiden withdrawal or reduction." | 1.31 | Insomnia related to biperiden withdrawal in two schizophrenic patients. ( Hirose, S, 2000) |
| "Haloperidol-induced c-fos was augmented in the striatum and pituitary, but reduced in the frontal cortex by chronic lithium treatment." | 1.30 | Basal and stimulated C-fos mRNA expression in the rat brain: effect of chronic dietary lithium. ( Mathé, AA; Miller, JC, 1997) |
| "In contrast, haloperidol catalepsy was not affected by the SCH23390 pretreatment." | 1.30 | Modification of cataleptic responses to dopamine receptor antagonists after withdrawal from chronic cocaine or cocaine plus dopamine antagonist administration. ( Akimoto, T; Mizuki, Y; Suetsugi, M; Ushijima, I; Yamada, M, 1998) |
| "The latency of the audiogenic seizures was prolonged by bromocriptine treatment." | 1.29 | Effects of bromocriptine and haloperidol on ethanol withdrawal syndrome in rats. ( Akarsu, ES; Kayaalp, SO; Uzbay, IT, 1994) |
| " Body clearance decreased nonsignificantly, and elimination half-life increased significantly after chronic dosing compared with kinetic parameters determined after a single dose." | 1.29 | The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. ( Bigelow, LB; DeVane, CL; Khot, V; Kirch, DG; Korpi, ER; Venable, D; Wyatt, RJ, 1993) |
| "Naloxone treatment had little effect on VCMs but increased catalepsy scores in both haloperidol and vehicle treated groups." | 1.29 | Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate. ( Egan, MF; Ferguson, JN; Hyde, TM, 1995) |
| " Haloperidol is often administered chronically in clinical situations; hence, it is important to investigate the effects of repeated, as well as acute, dosing with this drug." | 1.29 | Effect of repeated haloperidol administration on phencyclidine discrimination in rats. ( Wiley, JL, 1995) |
| "In haloperidol-treated rats hypersensitivity of the dopaminergic system developed at the end of 2 weeks' administration, as evidenced by depression of dopamine metabolism." | 1.29 | Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain. ( Antkiewicz-Michaluk, L; Karolewicz, B; Michaluk, J; Vetulani, J, 1996) |
| "All met DSM-III-R criteria for opioid dependence." | 1.29 | Methadone withdrawal psychosis. ( Galynker, II; Levinson, I; Rosenthal, RN, 1995) |
| "SCH23390 catalepsy had a rapid onset but a short duration, whereas haloperidol catalepsy had a slower onset and longer duration." | 1.29 | Development of tolerance and reverse tolerance to haloperidol- and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment. ( Mizuki, Y; Ushijima, I; Yamada, M, 1995) |
| " To the extent that the VCM syndrome models TD, the absence of long-term suppression of the VCM syndrome suggests that, at this dosage range, increasing depot neuroleptic doses may not be a useful long-term strategy for TD suppression." | 1.29 | Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose. ( Egan, MF; Hyde, TM; Kleinman, JE; Wyatt, RJ, 1995) |
| "Haloperidol and clozapine were rapidly withdrawn from a schizophrenic patient on separate occasions several months apart." | 1.28 | Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. ( Alphs, LD; Lee, HS, 1991) |
| "Development of neuroleptic malignant syndrome (NMS) following discontinuation of high-dose and high-potency neuroleptic agents is described." | 1.28 | Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment. ( Hermesh, H; Munitz, H; Spivak, B; Tyano, S; Weizman, A; Wolovick, L, 1990) |
| "RBC choline concentration was significantly lower in patients medicated with neuroleptics and cogentin." | 1.28 | RBC and plasma choline in neuroleptic-treated schizophrenic patients. ( Hanin, I; Jeste, DV; Kopp, U; Lawson, WB; Wyatt, RJ, 1989) |
| " Long-term administration of haloperidol resulted in supersensitivity of dopamine receptors." | 1.27 | Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined. ( Lapierre, YD; Rastogi, RB; Rastogi, SK; Singhal, RL, 1983) |
| "A patient with long-standing Tourette's syndrome had a dramatic exacerbation of symptoms following the rapid withdrawal of haloperidol." | 1.27 | Clonidine in the treatment of Tourette's syndrome exacerbation due to haloperidol withdrawal. ( Max, JE; Rasmussen, SA, 1986) |
| "Haloperidol was given first in doses of 1." | 1.27 | Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review. ( Domino, EF, 1985) |
| "Levels of the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) and of the major serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) were determined in the CSF of rats at various times after repeated electroshock treatment (EST) or chronic administration of haloperidol." | 1.27 | Dopamine and serotonin metabolites in rat cerebroventricular fluid following withdrawal of haloperidol or electroshock treatment. ( Barkai, AI; Kowalik, S; Reches, A, 1984) |
| "Most patients with mild withdrawal symptoms do not require hospitalization and respond to non-pharmacologic supportive care." | 1.27 | Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome. ( Naranjo, CA; Sellers, EM, 1986) |
| "Haloperidol was administered with the food at a concentration of 0." | 1.26 | Effect of haloperidol withdrawal on motor activity and circadian rhythm of rats. ( Chandra, O; Kumar, A; Saxena, PN, 1981) |
| "Fluphenazine decanoate was administered chronically to rats on a schedule for which marked tolerance developed to acute fluphenazine effects on several parameters of dopaminergic neuronal function." | 1.26 | Tolerance to fluphenazine and supersensitivity to apomorphine in central dopaminergic systems after chronic fluphenazine decanoate treatment. ( Roth, RH; Wheeler, SC, 1980) |
| "This suggests that symptoms of Gilles de la Tourette syndrome which appear after withdrawal of chronic neuroleptic therapy may be due to transient hypersensitivity of dopamine receptor sites." | 1.26 | Transient Gilles de la Tourette syndrome after chronic neuroleptic withdrawal. ( Singer, WD, 1981) |
| "Rats with ablated frontal sensorimotor cortex and one with ablated sensorimotor connections to forebrain showed more vacuous chewing movements following 6-week chronic administration of a neuroleptic than did occipitally damaged rats or normal controls who were treated in the same way." | 1.26 | Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia. ( Glassman, HN; Glassman, RB, 1980) |
| " Dose-response curves of apomorphine-stimulated motor activity and rearing behavior were shifted to the left when determined in mice during the period of withdrawal hyperactivity." | 1.25 | Supersensitivity to dopaminergic agonists induced by haloperidol. ( Moore, KE; Thornburg, JE, 1975) |
| "Pretreatment with haloperidol (0." | 1.25 | Narcotic withdrawal like mouse jumping produced by amphetamine and L-DOPA. ( Colpaert, FC; Laduron, P; Lal, H, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 127 (51.00) | 18.7374 |
| 1990's | 78 (31.33) | 18.2507 |
| 2000's | 35 (14.06) | 29.6817 |
| 2010's | 9 (3.61) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hardman, MI | 1 |
| Sprung, J | 1 |
| Weingarten, TN | 1 |
| Gill, KM | 1 |
| Cook, JM | 1 |
| Poe, MM | 1 |
| Grace, AA | 1 |
| Hollais, AW | 1 |
| Patti, CL | 1 |
| Zanin, KA | 1 |
| Fukushiro, DF | 4 |
| Berro, LF | 1 |
| Carvalho, RC | 2 |
| Kameda, SR | 1 |
| Frussa-Filho, R | 7 |
| Vo, KT | 1 |
| Horng, H | 1 |
| Smollin, CG | 1 |
| Benowitz, NL | 1 |
| Carvalho, Rde C | 1 |
| Ricardo, VP | 1 |
| Alvarez, Jdo N | 2 |
| Ribeiro, LT | 1 |
| Batool, F | 1 |
| Ahmed, S | 1 |
| Haleem, DJ | 2 |
| Helfer, DC | 1 |
| Callegaro-Filho, D | 1 |
| Trombin, TF | 1 |
| Zanlorenci, LH | 1 |
| Sanday, L | 1 |
| Silva, RH | 1 |
| Kovacs, N | 1 |
| Herold, R | 1 |
| Janszky, J | 1 |
| Komoly, S | 1 |
| Nagy, F | 1 |
| Chatterjee, M | 1 |
| Ganguly, S | 1 |
| Srivastava, M | 1 |
| Palit, G | 1 |
| Kim, YD | 1 |
| Kim, JS | 1 |
| Song, IU | 1 |
| Lee, KS | 1 |
| Kim, YI | 1 |
| Braña-Berríos, M | 1 |
| Lam, K | 1 |
| Coffey, B | 1 |
| Kashyap, GL | 1 |
| Patel, AG | 1 |
| Hsieh, HC | 1 |
| Li, HY | 1 |
| Lin, MY | 1 |
| Chiou, YF | 1 |
| Lin, SY | 1 |
| Wong, CH | 1 |
| Chen, JC | 1 |
| Scarr, E | 1 |
| Parkin, FM | 1 |
| Pavey, G | 1 |
| Dean, B | 1 |
| Smith, C | 1 |
| Felce, D | 1 |
| Ahmed, Z | 1 |
| Fraser, WI | 1 |
| Kerr, M | 1 |
| Kiernan, C | 1 |
| Emerson, E | 1 |
| Robertson, J | 1 |
| Allen, D | 1 |
| Baxter, H | 1 |
| Thomas, J | 1 |
| Khan, NH | 1 |
| De Souza, IE | 1 |
| Dawson, NM | 1 |
| Clifford, JJ | 1 |
| Waddington, JL | 2 |
| Meredith, GE | 1 |
| Stanley, KM | 2 |
| Amabile, CM | 1 |
| Simpson, KN | 2 |
| Couillard, D | 1 |
| Norcross, ED | 1 |
| Worrall, CL | 2 |
| CIANI, N | 1 |
| DONINI, G | 1 |
| Alevizos, B | 1 |
| Perry, JC | 1 |
| Vital, MA | 1 |
| Tufik, S | 1 |
| Palermo-Neto, J | 6 |
| Margetić, B | 1 |
| Aukst-Margetić, B | 1 |
| Sell, SL | 1 |
| McMahon, LR | 1 |
| Koek, W | 1 |
| France, CP | 1 |
| Tenn, CC | 1 |
| Fletcher, PJ | 1 |
| Kapur, S | 1 |
| Barrett, RJ | 4 |
| Caul, WF | 4 |
| Smith, R | 1 |
| Mendhekar, DN | 1 |
| Jiloha, RC | 1 |
| Moeller, KE | 1 |
| Barnes, BJ | 1 |
| Lunsford, SL | 1 |
| Miller, JG | 1 |
| Spencer, AP | 1 |
| Tariot, PN | 1 |
| Schneider, L | 1 |
| Katz, IR | 1 |
| Mintzer, JE | 1 |
| Street, J | 1 |
| Copenhaver, M | 1 |
| Williams-Hughes, C | 1 |
| Tatsu, JA | 1 |
| de Castro, JP | 1 |
| Chinen, CC | 1 |
| Overstreet, DH | 1 |
| Knapp, DJ | 1 |
| Breese, GR | 2 |
| Lin, CC | 1 |
| Bai, YM | 1 |
| Chen, JY | 1 |
| Wang, YC | 1 |
| Liou, YJ | 1 |
| Barkai, AI | 1 |
| Kowalik, S | 1 |
| Reches, A | 1 |
| Glassman, RB | 1 |
| Glassman, HN | 1 |
| Black, RF | 1 |
| Hoffman, PL | 1 |
| Tabakoff, B | 1 |
| Luchins, DJ | 1 |
| Freed, WJ | 1 |
| Wyatt, RJ | 5 |
| Lieberman, J | 1 |
| Faheem, AD | 1 |
| Brightwell, DR | 1 |
| Burton, GC | 1 |
| Struss, A | 1 |
| Rastogi, SK | 2 |
| Rastogi, RB | 2 |
| Singhal, RL | 2 |
| Lapierre, YD | 2 |
| Zharkovskiĭ, AM | 1 |
| Zharkovskaia, TA | 1 |
| DePaulo, JR | 1 |
| Feigenbaum, JJ | 1 |
| Yanai, J | 1 |
| Stoff, DM | 1 |
| Jeste, DV | 2 |
| Gillin, JC | 1 |
| Moja, EA | 1 |
| Cohen, L | 1 |
| Stauderman, KA | 1 |
| Sant, WW | 1 |
| Ellison, G | 1 |
| Scatton, B | 1 |
| Fage, D | 1 |
| Bernardi, MM | 4 |
| Mizes, JS | 1 |
| Gamble, SJ | 1 |
| De Souza, H | 1 |
| Palermo Neto, J | 1 |
| Ferrari, F | 2 |
| Baggio, G | 1 |
| Sato, M | 1 |
| Chen, CC | 1 |
| Akiyama, K | 1 |
| Otsuki, S | 1 |
| Montanaro, N | 2 |
| Dall'Olio, R | 2 |
| Gandolfi, O | 2 |
| Vaccheri, A | 2 |
| Kuruvilla, A | 1 |
| Fung, YK | 1 |
| Uretsky, NJ | 1 |
| De Veaugh-Geiss, J | 1 |
| Devanand, DP | 1 |
| Carey, RJ | 1 |
| Singer, WD | 1 |
| Mueller, J | 1 |
| Aminoff, MJ | 1 |
| Cools, AR | 1 |
| Uhde, TW | 1 |
| Redmond, DE | 1 |
| Kleber, HD | 1 |
| Deveaugh-Geiss, J | 1 |
| Pandurangi, A | 1 |
| Gordon, JH | 2 |
| Borison, RL | 1 |
| Diamond, BI | 2 |
| Wheeler, SC | 1 |
| Roth, RH | 1 |
| Samanin, R | 1 |
| Cervo, L | 1 |
| Rochat, C | 1 |
| Poggesi, E | 1 |
| Mennini, T | 1 |
| Kumar, A | 1 |
| Chandra, O | 1 |
| Saxena, PN | 1 |
| Burov, IuV | 2 |
| Viglinskaia, IV | 1 |
| Verimer, T | 1 |
| Long, JP | 1 |
| Flynn, JR | 1 |
| Arnerić, SP | 1 |
| Walsh, BJ | 1 |
| Pary, RJ | 1 |
| Klontz, W | 1 |
| Foxworth, JM | 1 |
| van Kammen, DP | 14 |
| Agren, H | 1 |
| Yao, JK | 8 |
| O'Connor, DT | 1 |
| Gurklis, J | 4 |
| Peters, JL | 6 |
| Kelley, ME | 4 |
| Gurklis, JA | 2 |
| Gilbertson, MW | 4 |
| Jaffe, E | 1 |
| Trémeau, F | 1 |
| Sharif, Z | 1 |
| Reider, R | 1 |
| Fukase, H | 1 |
| Fukuzaki, K | 1 |
| Koja, T | 1 |
| Nagata, R | 1 |
| Lukas, SE | 1 |
| Dawe, S | 1 |
| Gerada, C | 1 |
| Russell, MA | 1 |
| Gray, JA | 1 |
| Egan, MF | 2 |
| Hyde, TM | 2 |
| Kleinman, JE | 1 |
| Ushijima, I | 3 |
| Mizuki, Y | 3 |
| Yamada, M | 2 |
| Welker, JA | 1 |
| Levinson, I | 1 |
| Galynker, II | 1 |
| Rosenthal, RN | 1 |
| Steinpreis, RE | 1 |
| Baskin, P | 1 |
| Salamone, JD | 1 |
| Lublin, H | 2 |
| Gerlach, J | 2 |
| Peacock, L | 2 |
| Uzbay, IT | 1 |
| Akarsu, ES | 1 |
| Kayaalp, SO | 1 |
| Lipska, BK | 1 |
| Weinberger, DR | 1 |
| Forman, SD | 1 |
| Bissette, G | 1 |
| Yao, J | 3 |
| Nemeroff, CB | 1 |
| Lawson, WB | 2 |
| Karson, CN | 1 |
| Graham, SR | 1 |
| Kokkinidis, L | 2 |
| Silva, RR | 2 |
| Friedhoff, AJ | 1 |
| Alpert, M | 1 |
| Lang, AE | 1 |
| Borg, PJ | 1 |
| Taylor, DA | 1 |
| Dixon, L | 1 |
| Thaker, G | 1 |
| Conley, R | 1 |
| Ross, D | 1 |
| Cascella, N | 1 |
| Tamminga, C | 1 |
| Guidotti, A | 1 |
| Guarneri, P | 1 |
| Peters, J | 2 |
| Costa, E | 1 |
| Malone, RP | 1 |
| Anderson, LT | 1 |
| Shay, J | 1 |
| Campbell, M | 2 |
| Bruhwyler, J | 1 |
| Chleide, E | 1 |
| Houbeau, G | 1 |
| Waegeneer, N | 1 |
| Mercier, M | 1 |
| Chang, WH | 1 |
| Lin, SK | 1 |
| Juang, DJ | 1 |
| Chen, LC | 1 |
| Yang, CH | 1 |
| Hu, WH | 1 |
| Chien, CP | 2 |
| Lam, YW | 1 |
| Jann, MW | 2 |
| Khot, V | 1 |
| DeVane, CL | 1 |
| Korpi, ER | 1 |
| Venable, D | 1 |
| Bigelow, LB | 1 |
| Kirch, DG | 1 |
| Bronson, ME | 1 |
| Ferguson, JN | 1 |
| Wiley, JL | 1 |
| Spies, CD | 1 |
| Dubisz, N | 1 |
| Funk, W | 1 |
| Blum, S | 1 |
| Müller, C | 2 |
| Rommelspacher, H | 2 |
| Brummer, G | 1 |
| Specht, M | 1 |
| Hannemann, L | 1 |
| Striebel, HW | 1 |
| Antkiewicz-Michaluk, L | 2 |
| Karolewicz, B | 2 |
| Michaluk, J | 2 |
| Vetulani, J | 2 |
| Condray, R | 1 |
| Capasso, A | 1 |
| Sorrentino, L | 1 |
| Stanislav, SW | 1 |
| Miller, JC | 1 |
| Mathé, AA | 1 |
| Riker, RR | 1 |
| Fraser, GL | 1 |
| Richen, P | 1 |
| Bobba, R | 1 |
| Abílio, VC | 1 |
| Bergamo, M | 1 |
| Gauvin, DV | 1 |
| Briscoe, RJ | 1 |
| Baird, TJ | 1 |
| Vallett, M | 1 |
| Carl, KL | 1 |
| Holloway, FA | 1 |
| Modrego Pardo, P | 1 |
| Pérez Trullen, JM | 1 |
| Stadler, JR | 2 |
| Wolter-Henseler, DK | 1 |
| Cammarano, WB | 1 |
| Pittet, JF | 1 |
| Weitz, S | 1 |
| Schlobohm, RM | 1 |
| Marks, JD | 1 |
| Vital, MB | 1 |
| Suetsugi, M | 2 |
| Akimoto, T | 1 |
| Almeida, OP | 1 |
| Ballard, TM | 1 |
| McAllister, KH | 1 |
| Obuchowicz, E | 1 |
| Turchan, J | 1 |
| Lenzenhuber, E | 1 |
| Spies, C | 1 |
| Rodríguez-Arias, M | 1 |
| Pinazo, J | 1 |
| Miñarro, J | 1 |
| Stinus, L | 1 |
| Markianos, M | 2 |
| Moussas, G | 2 |
| Lykouras, L | 2 |
| Hatzimanolis, J | 2 |
| Allen, DN | 1 |
| Anastasiou, A | 1 |
| Goldstein, G | 1 |
| Gilbertson, M | 1 |
| Glazer, WM | 2 |
| Harvey, BH | 1 |
| Bester, A | 1 |
| Hirose, S | 1 |
| Kobayashi, T | 1 |
| Aoki, T | 1 |
| Usami, K | 1 |
| Watanabe, Y | 1 |
| Qiao, H | 1 |
| Noda, Y | 1 |
| Kamei, H | 1 |
| Nagai, T | 1 |
| Furukawa, H | 1 |
| Miura, H | 1 |
| Kayukawa, Y | 1 |
| Ohta, T | 1 |
| Nabeshima, T | 1 |
| Joyce, JN | 1 |
| Mullins, ME | 1 |
| Fitzmaurice, SC | 1 |
| Sharma, AN | 1 |
| Lombardi, MH | 1 |
| Illuzzi, FA | 1 |
| Nelson, LS | 1 |
| Glick, ID | 1 |
| Berg, PH | 1 |
| Marchese, G | 1 |
| Casu, MA | 1 |
| Bartholini, F | 1 |
| Ruiu, S | 1 |
| Saba, P | 1 |
| Gessa, GL | 1 |
| Pani, L | 1 |
| Russig, H | 1 |
| Murphy, CA | 1 |
| Feldon, J | 1 |
| Hine, B | 2 |
| Gershon, S | 2 |
| Belknap, JK | 1 |
| Baldino, F | 1 |
| Cowan, A | 1 |
| Geller, EB | 1 |
| Adler, MW | 1 |
| König, P | 1 |
| Sellers, EM | 2 |
| Asnis, GM | 1 |
| Sachar, EJ | 1 |
| Langer, G | 1 |
| Halpern, FS | 1 |
| Fink, M | 1 |
| Zaluzny, SG | 1 |
| Chesher, GB | 1 |
| Jackson, DM | 2 |
| Malor, R | 1 |
| Neto, JP | 1 |
| Lal, H | 8 |
| Dunstan, R | 1 |
| Coleman, JH | 1 |
| Evans, WE | 1 |
| Gianutsos, G | 1 |
| Puri, SK | 1 |
| Snyder, R | 1 |
| Olbrich, R | 1 |
| West, RR | 1 |
| Newgreen, DB | 1 |
| Gottschalk, LA | 1 |
| Cohn, JB | 1 |
| Brown, W | 1 |
| Drawbaugh, R | 1 |
| Hynes, M | 1 |
| Brown, G | 1 |
| Glick, SD | 1 |
| Cox, RD | 1 |
| Fink, H | 1 |
| Oelssner, W | 1 |
| Kalman, T | 1 |
| Warner, GM | 1 |
| Greenblatt, DJ | 1 |
| Gross, PL | 1 |
| Harris, J | 1 |
| Shader, RI | 1 |
| Ciraulo, DA | 1 |
| Laughren, TP | 1 |
| Brown, WA | 1 |
| Williams, BW | 1 |
| Ban, TA | 1 |
| Pecknold, JC | 1 |
| Caroli, F | 1 |
| Littre-Poirier, MF | 1 |
| Ginestet, D | 1 |
| Deniker, P | 1 |
| Palestine, ML | 2 |
| Alatorre, E | 1 |
| Wallace, ER | 1 |
| Staton, MA | 1 |
| Numan, R | 1 |
| Blum, K | 2 |
| Eubanks, JD | 2 |
| Wallace, JE | 2 |
| Schwertner, HA | 1 |
| Drawbaugh, RB | 1 |
| Hamilton, H | 1 |
| Tseng, LF | 1 |
| Brase, DA | 1 |
| Loh, HH | 1 |
| Colpaert, FC | 1 |
| Laduron, P | 1 |
| Sayers, AC | 1 |
| Bürki, HR | 1 |
| Ruch, W | 1 |
| Asper, H | 1 |
| Friedman, E | 2 |
| Torrelio, M | 1 |
| Thornburg, JE | 1 |
| Moore, KE | 1 |
| Bhat, RV | 1 |
| Worley, PF | 1 |
| Cole, AJ | 1 |
| Baraban, JM | 1 |
| White, DK | 1 |
| Borowski, TB | 1 |
| Steinhauer, SR | 1 |
| Colbert, K | 1 |
| Zubin, J | 1 |
| Kirkpatrick, B | 3 |
| Carpenter, WT | 2 |
| Maeda, K | 2 |
| Buchanan, RW | 2 |
| Breier, A | 1 |
| Tamminga, CA | 3 |
| Staudt, F | 1 |
| Linder, M | 1 |
| Lauterbach, EC | 1 |
| O'Connor, D | 1 |
| Nofzinger, E | 1 |
| Mateo, D | 1 |
| Muñoz-Blanco, JL | 1 |
| Giménez-Roldán, S | 1 |
| Neylan, TC | 1 |
| Maisami, M | 1 |
| Golant, D | 1 |
| Pucilowski, O | 1 |
| Eichelman, B | 1 |
| Kaliszuk, S | 1 |
| Borzecki, Z | 1 |
| Swies, Z | 1 |
| Gillman, MA | 1 |
| Lightigfeld, FJ | 1 |
| Minamisawa, S | 1 |
| Tezuka, T | 1 |
| Enomoto, K | 1 |
| Nozaki, Y | 1 |
| Funatomi, H | 1 |
| Hatta, Y | 1 |
| Franco, K | 1 |
| Tamburrino, M | 1 |
| Campbell, N | 1 |
| Pentz, J | 1 |
| Evans, C | 1 |
| Alphs, LD | 1 |
| Lee, HS | 1 |
| Kastrup, O | 1 |
| Eikmeier, G | 1 |
| Gastpar, M | 1 |
| Spivak, B | 1 |
| Weizman, A | 1 |
| Wolovick, L | 1 |
| Hermesh, H | 2 |
| Tyano, S | 1 |
| Munitz, H | 1 |
| Perez-Oso, E | 1 |
| Lopez-Ruiz, MP | 1 |
| Arilla, E | 1 |
| Matthews, P | 1 |
| Quinn, D | 1 |
| Marcoux, GS | 1 |
| Falkenberg, K | 1 |
| Wang, HY | 1 |
| Butkerait, P | 1 |
| Achiron, A | 1 |
| Melamed, E | 1 |
| van Kammen, WB | 1 |
| Nugent, A | 1 |
| Goetz, KL | 1 |
| Linnoila, M | 1 |
| Thaker, GK | 1 |
| Wagman, AM | 1 |
| Jauch, D | 1 |
| Fidone, GS | 1 |
| Hernandez, JM | 1 |
| Amrung, S | 1 |
| Davis, CM | 1 |
| Hanin, I | 1 |
| Kopp, U | 1 |
| Bagdy, G | 1 |
| Perényi, A | 1 |
| Frecska, E | 1 |
| Révai, K | 1 |
| Papp, Z | 1 |
| Fekete, MI | 1 |
| Arató, M | 1 |
| Sirota, P | 1 |
| Eviatar, J | 1 |
| Rupniak, NM | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Domino, EF | 1 |
| Campbell, A | 1 |
| Baldessarini, RJ | 2 |
| Hafez, HM | 1 |
| Benarroche, CL | 1 |
| Naranjo, CA | 1 |
| van der Laan, JW | 2 |
| Hillen, FC | 1 |
| Rosenbloom, A | 1 |
| Perry, R | 1 |
| Nobler, MS | 1 |
| Chahl, LA | 1 |
| Kavanagh, CA | 1 |
| Corlis, A | 1 |
| See, RE | 1 |
| Levin, ED | 1 |
| Ellison, GD | 1 |
| Kishnir, SL | 1 |
| Dorce, VA | 1 |
| Joshi, PT | 1 |
| Capozzoli, JA | 1 |
| Coyle, JT | 1 |
| Merriam, AE | 1 |
| Max, JE | 1 |
| Rasmussen, SA | 1 |
| Riddle, MA | 1 |
| Hardin, MT | 1 |
| Towbin, KE | 1 |
| Leckman, JF | 1 |
| Cohen, DJ | 1 |
| Kantz, RB | 1 |
| Horst, HM | 1 |
| Tampieri, A | 1 |
| Mangiafico, V | 1 |
| Borisenko, SA | 1 |
| Shukla, S | 1 |
| Turner, WJ | 1 |
| Newman, G | 1 |
| Grob, CS | 1 |
| Holtzman, SG | 1 |
| Napier, TC | 1 |
| Coyle, S | 1 |
| Drago, F | 1 |
| Kovács, GL | 1 |
| Szabo, G | 1 |
| Scapagnini, U | 1 |
| Telegdy, G | 1 |
| Cicero, TJ | 1 |
| Meyer, ER | 1 |
| Bell, RD | 1 |
| Avrutskii, GIa | 1 |
| Gurovich, IIa | 1 |
| Prokhorova, IS | 1 |
| Tirkel'taub, IuA | 1 |
| Romanov, IuD | 1 |
| Pozuelo, J | 1 |
| Kerr, FW | 1 |
| Franzén, G | 2 |
| Raft, DD | 1 |
| Newmark, C | 1 |
| Toomey, T | 1 |
| Aherwadkar, SJ | 1 |
| Efendigil, MC | 1 |
| Coulshed, N | 1 |
| Carranza-Acevedo, J | 1 |
| Estrada-Robles, U | 1 |
| Kazamatsuri, H | 1 |
| Cole, JO | 1 |
| Karkalas, J | 1 |
| LeCompte, G | 1 |
| Friedman, JJ | 1 |
| Sinacore, R | 1 |
| De Maio, D | 1 |
| Cookson, IB | 1 |
| Wells, PG | 1 |
| Puri, S | 1 |
| Pitt, B | 1 |
| Jacobson, G | 1 |
| Manschreck, T | 1 |
| Martin, WR | 1 |
| Eades, CG | 1 |
| Thompson, WO | 1 |
| Thompson, JA | 1 |
| Flanary, HG | 1 |
| Ford, CV | 1 |
| Gottlieb, F | 1 |
| Learoyd, BM | 1 |
| Devenyi, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal Among Adult Inpatients With Alcohol Dependence in an Ear, Nose, Throat and Jaw Surgery Department[NCT02782156] | 89 participants (Actual) | Observational | 2014-11-30 | Completed | |||
| Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study[NCT02318290] | 54 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Opioid Withdrawal Symptoms in Critically Ill Patients[NCT03374722] | 55 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults[NCT03435614] | 29 participants (Actual) | Observational | 2018-02-26 | Completed | |||
| Assessing Current Analgesia and Sedation Weaning Practices in Adult Critically Ill Patients[NCT04422808] | 2,437 participants (Actual) | Observational | 2021-06-01 | Completed | |||
| Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation[NCT05351333] | 66 participants (Anticipated) | Interventional | 2022-08-03 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Percentage of daily assessments associated with each of the following signs and symptoms experienced by patients with and without OIWS (Restlessness (Richmond Agitation-Sedation scale = 1), Agitation (RASS > 1), Anxiety, Hallucinations, Insomnia/sleep disturbance (< 4 hours of continuous sleep), Mydriasis (Pupil diameter > 2 mm) and systolic blood pressure (SBP) > 140 mmHg. These assessments were performed once daily.~Note that for the group of patients experiencing IWS, the data on signs and symptoms are limited to the assessment on the day that patients experienced OIWS.~The signs and symptoms presented (Restlessness; Agitation; Anxiety, Hallucinations, Insomnia/sleep disturbance; mydriasis; SBP > 140) were selected based on a > 15 % absolute difference between both groups which was judged to be clinically significant." (NCT03435614)
Timeframe: From first day of opioid dose reduction until transfer out of Intensive care unit (ICU) or a maximum of 14 days, including one further assessment post-ICU transfer
| Intervention | percentage of assessments (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Restlessness (RASS = 1) | Agitation (RASS > 1) | Anxiety | Hallucinations | Insomnia/Sleep disturbance (< 4 hours of continuous sleep) | Mydriasis (pupil size > 2mm) | Systolic Blood Pressure (SBP) > 140 mmHg | |
| IWS Negative | 13.6 | 4.9 | 30.6 | 11.2 | 21.4 | 77.8 | 53 |
| IWS Positive | 28.6 | 28.6 | 57.1 | 28.6 | 66.7 | 100 | 85.7 |
12 reviews available for haloperidol and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.
Topics: Akathisia, Drug-Induced; Baclofen; Cyproheptadine; Dexmedetomidine; Diphenhydramine; GABA-A Receptor | 2019 |
Lithium.
Topics: Aggression; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, C | 1984 |
Evidence for the involvement of central dopaminergic receptors in the acute and chronic effects induced by barbiturates.
Topics: Adenylyl Cyclases; Animals; Barbiturates; Brain; Chlorpromazine; Dopamine; Drug Interactions; Drug T | 1983 |
Rapid development of hypersensitivity and hyposensitivity to apomorphine and haloperidol: role of norepinephrine receptor mechanisms in CNS.
Topics: Animals; Apomorphine; Behavior, Animal; Brain; Dopamine; Haloperidol; Humans; Norepinephrine; Recept | 1980 |
Withdrawal akathisia: case reports and a proposed classification of chronic akathisia.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Bipolar Disorder; Dose-Response Relationship, Drug; Drug | 1994 |
Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients.
Topics: Adult; Critical Care; Delirium; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Infusions, In | 1997 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
Antianxiety drugs in alcohol withdrawal.
Topics: Alcoholism; Anti-Anxiety Agents; Benzodiazepines; Ethanol; Haloperidol; Humans; Lithium; Propranolol | 1978 |
Narcotic dependence, narcotic action and dopamine receptors.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Behavior, Animal; Brain; Corpus Striatum; Cyclic AMP; Dopam | 1975 |
Haloperidol in the therapy of severe behavior disorders.
Topics: Benperidol; Bipolar Disorder; Child Behavior; Dementia; Droperidol; Haloperidol; Humans; Neurocognit | 1976 |
Emerging treatment options in the alcohol withdrawal syndrome.
Topics: Adrenergic beta-Antagonists; Alcohol Withdrawal Delirium; Benzodiazepines; Drug Therapy, Combination | 1988 |
Management of alcohol withdrawal in the critically ill patient: a selected review.
Topics: Barbiturates; Benzodiazepines; Ethanol; Haloperidol; Humans; Paraldehyde; Substance Withdrawal Syndr | 1986 |
20 trials available for haloperidol and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Bri | 2006 |
Nicotine intake in smokers increases following a single dose of haloperidol.
Topics: Adult; Haloperidol; Humans; Male; Nicotine; Reward; Self Administration; Smoking; Substance Withdraw | 1995 |
Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.
Topics: Adult; Chronic Disease; Corticotropin-Releasing Hormone; Double-Blind Method; Haloperidol; Humans; M | 1994 |
Memory and plasma HVA changes in schizophrenia: are they episode markers?
Topics: Adult; Biomarkers; Cognition Disorders; Double-Blind Method; Haloperidol; Homovanillic Acid; Humans; | 1994 |
Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; | 1993 |
CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
Topics: Adult; Arousal; Brain; Carrier Proteins; Diazepam Binding Inhibitor; Dopamine; gamma-Aminobutyric Ac | 1993 |
Prophylaxis of alcohol withdrawal syndrome in alcohol-dependent patients admitted to the intensive care unit after tumour resection.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Chlormethiazole; Clonidine; Critical Care | 1995 |
[Gamma-hydroxybutyrate for treatment of alcohol withdrawal syndrome in intensive care patients. A comparison between with two symptom-oriented therapeutic concepts].
Topics: Adrenergic alpha-Agonists; Aged; Alkalosis, Respiratory; Anti-Anxiety Agents; Antipsychotic Agents; | 1999 |
Influence of haloperidol on the relationship of frontal lobe function to psychomotor poverty and disorganization syndromes.
Topics: Adult; Antipsychotic Agents; Benztropine; Cross-Over Studies; Double-Blind Method; Frontal Lobe; Hal | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male | 2002 |
Haloperidol in barbiturate detoxification.
Topics: Adolescent; Adult; Barbiturates; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Fem | 1977 |
[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Fluph | 1975 |
Control of acute alcoholic withdrawal symptoms: a comparative study of haloperidol and chlordiazepoxide.
Topics: Adult; Aged; Alcoholism; Chlordiazepoxide; Clinical Trials as Topic; Female; Haloperidol; Humans; In | 1976 |
Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.
Topics: Adult; Arousal; Double-Blind Method; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; | 1992 |
Molindone and haloperidol in tardive dyskinesia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Dy | 1985 |
Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
Topics: Adult; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Evaluatio | 1973 |
Drug treatment of the alcohol withdrawal syndrome and delirium tremens. A comparison of haloperidol with mesoridazine and hydroxyzine.
Topics: Adult; Aged; Alcoholism; Clinical Trials as Topic; Female; Haloperidol; Humans; Hydroxyzine; Injecti | 1973 |
A comparison of haloperidol with methadone in blocking heroin-withdrawal symptoms. A pilot study.
Topics: Adolescent; Adult; Clinical Trials as Topic; Haloperidol; Heroin Dependence; Humans; Methadone; Pilo | 1973 |
An objective evaluation of haloperidol in Gilles de la Tourette's syndrome.
Topics: Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Aged; Placebos; Substance | 1969 |
218 other studies available for haloperidol and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Diazepam; Disea | 2014 |
Effects of acute and long-term typical or atypical neuroleptics on morphine-induced behavioural effects in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Female; Haloperidol; Mice; Morphine; Motor Activity | 2014 |
Severe Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose.
Topics: Adult; Carisoprodol; Dexmedetomidine; Drug Overdose; Fentanyl; Haloperidol; Humans; Hypnotics and Se | 2017 |
Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cocaine; Cocaine-Related Disorders; Haloperidol; Hu | 2008 |
Dietary supplementations of amino acids: evidence for enhanced serotonergic functions following haloperidol withdrawal in rat medial prefrontal cortex.
Topics: Animals; Catalepsy; Dietary Supplements; Frontal Lobe; Haloperidol; Male; Rats; Rats, Wistar; Seroto | 2009 |
Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Topics: Amphetamine-Related Disorders; Animals; Antipsychotic Agents; Apomorphine; Corpus Striatum; Dopamine | 2009 |
Tics status: a movement disorder emergency: observations.
Topics: Adolescent; Antipsychotic Agents; Clonazepam; Creatine Kinase; Diagnostic and Statistical Manual of | 2011 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine | 2011 |
Recurrence of hyperglycemic-induced chorea-ballismus after haloperidol withdrawal.
Topics: Aged, 80 and over; Antipsychotic Agents; Chorea; Haloperidol; Humans; Hyperglycemia; Male; Recurrenc | 2011 |
Dysphoria associated with neuroleptic withdrawal in an adolescent with Tourette's disorder.
Topics: Adolescent; Affective Symptoms; Antipsychotic Agents; Benztropine; Haloperidol; Humans; Male; Parasy | 2011 |
Unusual presentation of a patient with GBL withdrawal: a case report.
Topics: 4-Butyrolactone; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chlorpromazine; Delirium; Hal | 2011 |
Spatial and temporal profile of haloperidol-induced immediate-early gene expression and phosphoCREB binding in the dorsal and ventral striatum of amphetamine-sensitized rats.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Basal Ganglia; Cyclic AMP Response Element-Bind | 2002 |
Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Haloperidol; Ion C | 2002 |
Sedation effects on responsiveness: evaluating the reduction of antipsychotic medication in people with intellectual disability using a conditional probability approach.
Topics: Adult; Aged; Antipsychotic Agents; Behavior Therapy; Combined Modality Therapy; Drug Administration | 2002 |
Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Basal Ganglia Diseases; Dopamine Antagonists; Drug | 2003 |
Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal.
Topics: Animals; Behavior, Animal; Dopamine Antagonists; Dyskinesia, Drug-Induced; Exploratory Behavior; Hal | 2003 |
Impact of an alcohol withdrawal syndrome practice guideline on surgical patient outcomes.
Topics: Adolescent; Adult; Aged; Alcohol-Related Disorders; Clonidine; Ethanol; Female; Haloperidol; Humans; | 2003 |
[ON THERAPEUTIC EFFICACY OF SUDDEN SUSPENSION OF PROLONGED THERAPY WITH ASSOCIATED RESERPINE AND CHLORPROMAZINE IN SCHIZOPHRENIC SUBJECTS].
Topics: Chlorpromazine; Drug Therapy; Haloperidol; Humans; Phenothiazines; Reserpine; Schizophrenia; Substan | 1965 |
Dependence and chronic psychosis with D-nor-pseudoephedrine.
Topics: Antipsychotic Agents; Appetite; Appetite Depressants; Benzodiazepines; Central Nervous System Stimul | 2003 |
Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Dopamine Agonists; Dopamine Antagonist | 2004 |
Neuroleptic malignant syndrome and clozapine withdrawal at the same time?
Topics: Adult; Antipsychotic Agents; Clozapine; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; P | 2005 |
Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys.
Topics: Adrenergic alpha-Agonists; Amphetamine; Analgesics, Opioid; Animals; Antidepressive Agents, Tricycli | 2005 |
A putative animal model of the "prodromal" state of schizophrenia.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Anim | 2005 |
Withdrawal, tolerance, and sensitization to dopamine mediated interoceptive cues in rats trained on a three-lever drug-discrimination task.
Topics: Amphetamine; Animals; Cues; Discrimination Learning; Dopamine; Dopamine Agonists; Dopamine Antagonis | 2005 |
Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation.
Topics: Adult; Anti-Anxiety Agents; Antiparkinson Agents; Antipsychotic Agents; Bromocriptine; Clozapine; Cr | 2005 |
Compliance of an institution-specific alcohol withdrawal protocol with evidence-based practice guidelines.
Topics: Adrenergic alpha-Agonists; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Clonidine; Ethanol; Evi | 2006 |
Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cocaine; Conditioning, Operant; Dopamine Antagonist | 2007 |
Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.
Topics: Alcohol Drinking; Aminopyridines; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzodiaz | 2007 |
Treatment of clozapine-associated tardive dyskinesia.
Topics: Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Clozapine; Cross-Over Studies; Dibenzothiepins; | 2008 |
Dopamine and serotonin metabolites in rat cerebroventricular fluid following withdrawal of haloperidol or electroshock treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Electroshock; Haloperidol; Homovanillic Acid; Hum | 1984 |
Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain; Chlorpromazine; Di | 1980 |
Receptor-mediated dopaminergic function after ethanol withdrawal.
Topics: Alcoholism; Animals; Apomorphine; Brain; Dihydroxyphenylalanine; Dopamine; Haloperidol; Humans; Male | 1980 |
The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Halop | 1980 |
Cholinergic rebound in neuroleptic withdrawal syndromes.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Receptors, Cholinergic; Substance Withdrawal | 1981 |
Respiratory dyskinesia and dysarthria from prolonged neuroleptic use: tardive dyskinesia?
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dysarthria | 1982 |
Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.
Topics: Animals; Apomorphine; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Glutamate Decarboxy | 1983 |
[Changes in the number of benzodiazepine receptors in different parts of the brain of rats after neuroleptic withdrawal].
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Flunitrazepam; Haloperidol; Humans; Male; Rats; Rat | 1984 |
Behavioral supersensitivity to beta-phenylethylamine after chronic administration of haloperidol.
Topics: Animals; Corpus Striatum; Dextroamphetamine; Haloperidol; Humans; Male; Motor Activity; Phenethylami | 1984 |
Drug holidays alter onset of oral movements in rats following chronic haloperidol.
Topics: Animals; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Mastic | 1984 |
Hypophysectomy fails to affect the supersensitivity of striatal dopamine target cells induced by prolonged haloperidol treatment.
Topics: Acetylcholine; Animals; Apomorphine; Body Weight; Brain Chemistry; Corpus Striatum; Dopamine; Ergoli | 1984 |
Effects of apomorphine administration on rearing activity of control and experimental rats withdrawn from long-term haloperidol treatment.
Topics: Animals; Apomorphine; Haloperidol; Humans; Male; Motor Activity; Rats; Rats, Inbred Strains; Stereot | 1984 |
Effects of apomorphine administration on locomotor activity of control and experimental rats withdrawn from long-term haloperidol treatment.
Topics: Animals; Apomorphine; Haloperidol; Humans; Male; Motor Activity; Rats; Rats, Inbred Strains; Recepto | 1983 |
Phobic behavior after haloperidol withdrawal.
Topics: Adolescent; Blinking; Haloperidol; Humans; Male; Phobic Disorders; Stereotyped Behavior; Substance W | 1984 |
Spontaneous activity and apomorphine stereotypy during and after withdrawal from 3 1/2 months continuous administration of haloperidol: some methodological issues.
Topics: Animals; Apomorphine; Body Weight; Haloperidol; Humans; Male; Motor Activity; Rats; Stereotyped Beha | 1980 |
Effects of single and long-term haloperidol administration on open field behavior of rats.
Topics: Animals; Behavior, Animal; Brain Chemistry; Dopamine; Environment; Haloperidol; Humans; Male; Rats; | 1981 |
Influence of lisuride on morphine withdrawal signs in the rat: a dopamine-mimetic effect.
Topics: Aggression; Animals; Apomorphine; Dopamine; Ergolines; Haloperidol; Humans; Lisuride; Male; Morphine | 1982 |
Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis.
Topics: Adult; Delusions; Hallucinations; Haloperidol; Humans; Male; Methamphetamine; Paranoid Disorders; Ps | 1983 |
Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol.
Topics: Animals; Apomorphine; Behavior, Animal; Exploratory Behavior; Haloperidol; Humans; Male; Motor Activ | 1982 |
BehavioraL and biochemical changes caused by muscimol in mice withdrawN from haloperidol administration.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Haloperidol; Homovanillic Acid; Humans; Male; | 1982 |
Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
Topics: Animals; Apomorphine; Benztropine; Corpus Striatum; Dose-Response Relationship, Drug; Haloperidol; H | 1982 |
Bromocriptine-induced changes in dopamine and gamma aminobutyric acid in haloperidol withdrawn rats.
Topics: Animals; Bromocriptine; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Haloperidol; Humans; Mot | 1982 |
Transient Gilles de la Tourette syndrome after chronic neuroleptic withdrawal.
Topics: Adolescent; Chlorpromazine; Drug Hypersensitivity; Haloperidol; Humans; Male; Receptors, Dopamine; S | 1981 |
Tourette-like syndrome after long-term neuroleptic drug treatment.
Topics: Adult; Chlorpromazine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Substance Withdrawal Syn | 1982 |
Psychosis in the opioid addicted patient: assessment and treatment.
Topics: Adult; Chlorpromazine; Diagnosis, Differential; Double-Blind Method; Haloperidol; Heroin Dependence; | 1982 |
Confusional paranoid psychosis after withdrawal from sympathomimetic amines: two case reports.
Topics: Adult; Aged; Depression; Dextroamphetamine; Diethylpropion; Female; Haloperidol; Humans; Male; Obesi | 1982 |
Estrogen in experimental tardive dyskinesia.
Topics: Animals; Apomorphine; Castration; Dyskinesia, Drug-Induced; Estradiol; Female; Haloperidol; Humans; | 1980 |
Tolerance to fluphenazine and supersensitivity to apomorphine in central dopaminergic systems after chronic fluphenazine decanoate treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Brain; Brain Chemistry; Cerebral Cortex; Corpu | 1980 |
Reduction in the number of serotonin receptors in the brainstem of morphine dependent rats: relation to blockade of naloxone precipitated jumping by serotonin agonists.
Topics: Animals; Behavior, Animal; Brain Stem; Clonidine; Haloperidol; Humans; Male; Morphine Dependence; Na | 1980 |
Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dyski | 1981 |
Behavioral supersensitivity to methamphetamine following chronic treatment with (--)-sulpiride in the rat.
Topics: Animals; Behavior, Animal; Drug Interactions; Haloperidol; Humans; Male; Methamphetamine; Motor Acti | 1981 |
Effect of haloperidol withdrawal on motor activity and circadian rhythm of rats.
Topics: Animals; Circadian Rhythm; Diet; Female; Haloperidol; Humans; Male; Motor Activity; Rats; Substance | 1981 |
[Effect of psychotropic drugs on sleep disorders in rats during alcohol withdrawal].
Topics: Alcoholism; Animals; Anti-Anxiety Agents; Apomorphine; Benzodiazepines; Benzodiazepinones; Haloperid | 1981 |
Subsensitivity of the presynaptic dopamine receptors in cat heart after the termination of chronic haloperidol treatment.
Topics: Animals; Apomorphine; Blood Pressure; Cats; Female; Haloperidol; Heart; Humans; In Vitro Techniques; | 1981 |
Cholinergic rebounds and withdrawal syndromes.
Topics: Benztropine; Doxepin; Haloperidol; Humans; Male; Receptors, Cholinergic; Substance Withdrawal Syndro | 1980 |
Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
Topics: Adult; Chromogranin A; Chromogranins; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Ac | 1994 |
Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
Topics: Adult; Age of Onset; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Logistic Mode | 1995 |
Clozapine in tardive Tourette syndrome.
Topics: Adult; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Injections, I | 1995 |
Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys.
Topics: Animals; Behavior, Animal; Buprenorphine; Butorphanol; Haloperidol; Imipramine; Macaca fascicularis; | 1994 |
Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.
Topics: Animals; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ha | 1995 |
Development of tolerance and reverse tolerance to haloperidol- and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment.
Topics: Animals; Benzazepines; Catalepsy; Dose-Response Relationship, Drug; Drug Tolerance; Haloperidol; Mal | 1995 |
Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition.
Topics: Adult; Chromatography, Gas; Erythrocyte Membrane; Fatty Acids; Fatty Acids, Unsaturated; Haloperidol | 1994 |
Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures.
Topics: Adult; Erythrocyte Deformability; Erythrocyte Membrane; Fatty Acids; Fatty Acids, Unsaturated; Halop | 1994 |
Methadone withdrawal psychosis.
Topics: Adult; Female; Follow-Up Studies; Haloperidol; Humans; Male; Methadone; Middle Aged; Opioid-Related | 1995 |
Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine.
Topics: Animals; Basal Ganglia Diseases; Haloperidol; Jaw; Male; Movement; Rats; Rats, Sprague-Dawley; Scopo | 1993 |
Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
Topics: Animals; Basal Ganglia Diseases; Behavior, Animal; Benzazepines; Cebus; Dopamine; Dopamine D2 Recept | 1993 |
Effects of bromocriptine and haloperidol on ethanol withdrawal syndrome in rats.
Topics: Acoustic Stimulation; Alcohol Drinking; Animals; Behavior, Animal; Bromocriptine; Dopamine; Ethanol; | 1994 |
Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage.
Topics: Animals; Animals, Newborn; Apomorphine; Clozapine; Female; Haloperidol; Hippocampus; Ibotenic Acid; | 1994 |
Clinical correlates of body weight changes in schizophrenia.
Topics: Adult; Atrophy; Brain; Cerebral Ventricles; Energy Intake; Female; Haloperidol; Humans; Male; Psychi | 1994 |
Clozapine inhibits limbic system kindling: implications for antipsychotic action.
Topics: Acetylcholine; Amygdala; Animals; Antipsychotic Agents; Clozapine; Dopamine; Drug Interactions; Elec | 1993 |
Neuroleptic withdrawal psychosis in Tourette's disorder.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Long-Term Care; Male; Psychoses, Substance-Induced | 1993 |
Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity.
Topics: Adult; Anisotropy; Dose-Response Relationship, Drug; Erythrocyte Deformability; Erythrocyte Membrane | 1994 |
Voluntary oral morphine self-administration in rats: effect of haloperidol or ondansetron.
Topics: Animals; Behavior, Animal; Defecation; Haloperidol; Injections, Intramuscular; Male; Morphine; Morph | 1994 |
Haloperidol withdrawal and weight changes in autistic children.
Topics: Autistic Disorder; Body Weight; Child; Child, Preschool; Female; Haloperidol; Humans; Male; Prospect | 1993 |
Differentiation of haloperidol and clozapine using a complex operant schedule in the dog.
Topics: Animals; Clozapine; Conditioning, Operant; Dogs; Haloperidol; Male; Motor Activity; Reinforcement Sc | 1993 |
Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
Topics: Adult; Female; Half-Life; Haloperidol; Humans; Injections, Intramuscular; Male; Metabolic Clearance | 1993 |
The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Mon | 1993 |
Withdrawal from chronic haloperidol substitutes for the pentylenetetrazol discriminative stimulus.
Topics: Animals; Dose-Response Relationship, Drug; Haloperidol; Pentylenetetrazole; Rats; Rats, Inbred Strai | 1993 |
Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Dyskinesia, Drug-Induced; Grooming; Haloperidol; Male; N | 1995 |
Effect of repeated haloperidol administration on phencyclidine discrimination in rats.
Topics: Animals; Discrimination Learning; Discrimination, Psychological; Dopamine Antagonists; Dose-Response | 1995 |
Differences between haloperidol- and pimozide-induced withdrawal syndrome: a role for Ca2+ channels.
Topics: Animals; Antipsychotic Agents; Apomorphine; Calcium Channels; Haloperidol; Male; Motor Activity; Nif | 1995 |
Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain.
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Dopamine; Drug Administration Schedule; Extrapyrami | 1996 |
Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients.
Topics: Adult; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schi | 1996 |
Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; A | 1997 |
Cognitive effects of antipsychotic agents in persons with traumatic brain injury.
Topics: Adult; Antipsychotic Agents; Brain Damage, Chronic; Brain Injuries; Cognition Disorders; Haloperidol | 1997 |
Basal and stimulated C-fos mRNA expression in the rat brain: effect of chronic dietary lithium.
Topics: Amino Acid Isomerases; Animals; Blotting, Northern; Brain Chemistry; Carrier Proteins; Cholinergic A | 1997 |
Severe extrapyramidal side effects when discontinuing clozapine and starting haloperidol.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Dys | 1997 |
Behavioural subsensitivity induced by long-term administration of a low dose of haloperidol to rats.
Topics: Administration, Oral; Animals; Apomorphine; Autoreceptors; Behavior, Animal; Dopamine Agonists; Dopa | 1997 |
Physiological and subjective effects of acute cocaine withdrawal (crash) in rats.
Topics: Animals; Body Temperature; Cocaine; Discrimination Learning; Electroencephalography; Haloperidol; In | 1997 |
[Acute recurrent dystonia secondary to neuroleptic suppression].
Topics: Acute Disease; Antipsychotic Agents; Dystonia; Haloperidol; Humans; Male; Middle Aged; Recurrence; S | 1997 |
Amphetamine-induced withdrawal responding: effects of repeated drug administration.
Topics: Amphetamine; Animals; Conditioning, Operant; Discrimination Learning; Dopamine Antagonists; Dopamine | 1997 |
[Optical hallucinosis during benzodiazepine withdrawal in low-dose dependence].
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Hallucina | 1997 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Monosialoganglioside increased the in vivo affinity of D2 receptors for apomorphine in supersensitive rats.
Topics: Animals; Antipsychotic Agents; Apomorphine; Corpus Striatum; G(M1) Ganglioside; Haloperidol; Kinetic | 1998 |
Modification of cataleptic responses to dopamine receptor antagonists after withdrawal from chronic cocaine or cocaine plus dopamine antagonist administration.
Topics: Animals; Antipsychotic Agents; Catalepsy; Cocaine; Dopamine Agonists; Dopamine Uptake Inhibitors; Ha | 1998 |
Olanzapine for the treatment of tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Biperiden; Dyskinesia, Drug-Induced; Female; Haloperido | 1998 |
Acutely administered clozapine does not modify naloxone-induced withdrawal jumping in morphine-dependent mice.
Topics: Analgesics; Animals; Antipsychotic Agents; Clonidine; Clozapine; Haloperidol; Male; Mice; Morphine D | 1999 |
Effects of acute or long-term treatment with chlorpromazine, haloperidol or sulpiride on neuropeptide Y-like immunoreactivity concentrations in the nucleus accumbens of rat.
Topics: Animals; Antipsychotic Agents; Chlorpromazine; Dopamine Antagonists; Dopamine D2 Receptor Antagonist | 1999 |
Characterizing withdrawal in rats following repeated drug administration using an amphetamine-vehicle-haloperidol drug discrimination.
Topics: Amphetamine; Animals; Discrimination Learning; Dopamine Agents; Dopamine Antagonists; Haloperidol; I | 1999 |
Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice.
Topics: Aggression; Animals; Antipsychotic Agents; Benzazepines; Dopamine Antagonists; Haloperidol; Male; Mi | 1999 |
Dopamine receptor responsivity in alcoholic patients before and after detoxification.
Topics: Adult; Alcoholism; Brain; Ethanol; Haloperidol; Humans; Male; Middle Aged; Prolactin; Receptors, Dop | 2000 |
Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment.
Topics: Animals; Antipsychotic Agents; Brain Mapping; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; | 2000 |
Insomnia related to biperiden withdrawal in two schizophrenic patients.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Biperiden; Female; Haloperidol; Humans; Middle Ag | 2000 |
Effects of pertussis toxin on behavioral responses during different withdrawal periods from chronic cocaine treatment.
Topics: Adenosine Diphosphate Ribose; Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Catalep | 2000 |
Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Hallucinogens; Haloperidol; Male; Mice; | 2001 |
D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.
Topics: Animals; Brain; Dopamine Antagonists; Drug Administration Schedule; Haloperidol; Iodine Radioisotope | 2001 |
Lack of efficacy of benzodiazepines in treating gamma-hydroxybutyrate withdrawal.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Haloperidol; Humans; Lorazepam; Male; Sodium Oxyba | 2001 |
Changes in dopamine receptor responsivity during alcohol detoxification may predict relapse.
Topics: Adult; Alcoholism; Analysis of Variance; Dopamine Antagonists; Haloperidol; Humans; Male; Middle Age | 2001 |
Management of gamma-hydroxybutyrate withdrawal.
Topics: Emergency Service, Hospital; Haloperidol; Humans; Sodium Oxybate; Substance Withdrawal Syndrome | 2001 |
Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing.
Topics: Amisulpride; Animals; Antipsychotic Agents; Clozapine; Dopamine; Dose-Response Relationship, Drug; D | 2002 |
Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal.
Topics: Amphetamine; Animals; Antipsychotic Agents; Avoidance Learning; Central Nervous System Stimulants; C | 2002 |
Haloperidol attenuation of morphine abstinence: synergistic effect of acute lithium administration.
Topics: Animals; Drug Synergism; Haloperidol; Humans; Lithium; Male; Methyltyrosines; Morphine Dependence; N | 1977 |
Barbiturate physical dependence in mice: effects of neuroleptics and diazepam on the withdrawal syndrome.
Topics: Animals; Antipsychotic Agents; Barbiturates; Chlorpromazine; Diazepam; Haloperidol; Humans; Male; Me | 1978 |
Effects of antipsychotic and antianxiety drugs on the morphine abstinence syndrome in rats.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Behavior, Animal; Body Weight; Chlordiazepoxide; | 1979 |
[Psychiatric intensive therapy after acute alkaloid withdrawal syndrome].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Catheterization; Chlorprothixene; Ergotamine; Haloper | 1979 |
Normal prolactin responses in tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Prola | 1979 |
The attenuation of delta 9-tetrahydrocannabinol and morphine of the quasi-morphine withdrawal syndrome in rats.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Behavior, Animal; Chlordiazepoxide; Dronabinol; Haloperidol; H | 1979 |
Effects of abrupt and gradual withdrawal from long-term haloperidol treatment on open field behavior of rats.
Topics: Animals; Behavior, Animal; Defecation; Grooming; Haloperidol; Humans; Male; Motor Activity; Rats; Su | 1979 |
Further evidence for a change in central alpha-adrenergic receptor sensitivity after withdrawal from long-term haloperidol treatment.
Topics: Animals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Drug Interactions; Haloperidol; Human | 1978 |
Pharmacotherapy of the acute alcohol withdrawal syndrome.
Topics: Alcoholism; Anti-Anxiety Agents; Barbiturates; Chemical and Drug Induced Liver Injury; Chloral Hydra | 1975 |
A comparison of narcotic analgesics with neuroleptics on behavioral measures of dopaminergic activity.
Topics: Aggression; Amphetamine; Analgesics, Opioid; Animals; Apomorphine; Behavior, Animal; Brain; Cataleps | 1975 |
Alcohol withdrawal states and the need for treatment.
Topics: Adult; Alcoholism; Chlormethiazole; Drug Therapy, Combination; Emergencies; Female; Haloperidol; Hum | 1979 |
Choreiform movements induced by anticholinergic therapy.
Topics: Adolescent; Benztropine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Parasympatholytics; Su | 1979 |
Studies of cognitive function as influenced by administration of haloperidol or diazepam in detoxification of acute alcoholics.
Topics: Adult; Alcoholism; Cognition; Diazepam; Double-Blind Method; Female; Haloperidol; Humans; Male; Perc | 1979 |
Enhanced prolactin inhibition following chronic treatment with haloperidol and morphine.
Topics: Animals; Apomorphine; Dopamine; Haloperidol; Humans; Hypothalamus; Male; Morphine; Neural Pathways; | 1977 |
Changes in sensitivity to operant effects of dopaminergic and cholinergic agents following morphine withdrawal in rats.
Topics: Animals; Apomorphine; Conditioning, Operant; Dopamine; Female; Haloperidol; Humans; Morphine; Piloca | 1977 |
[Effect of psychotomimetics and haloperidol on head twitching following alcohol withdrawal in mice].
Topics: Animals; Ethanol; Hallucinogens; Haloperidol; Humans; Lysergic Acid Diethylamide; Male; Mescaline; M | 1978 |
Protracted vomiting following abrupt cessation of psychotropics: a case report.
Topics: Adult; Benztropine; Depression; Drug Therapy, Combination; Haloperidol; Humans; Imipramine; Male; Sc | 1978 |
Fatal hyperthermia following haloperidol therapy of sedative-hypnotic withdrawal.
Topics: Adult; Barbiturates; Dose-Response Relationship, Drug; Fever; Haloperidol; Humans; Male; Methaqualon | 1978 |
Serum prolactin and clinical state during neuroleptic treatment and withdrawal.
Topics: Adult; Alcoholism; Haloperidol; Humans; Hysteria; Male; Middle Aged; Prolactin; Psychiatric Status R | 1979 |
Acute hypertension after abrupt withdrawal of antipsychotic medication.
Topics: Adolescent; Benztropine; Fluphenazine; Haloperidol; Humans; Hypertension; Male; Schizophrenia; Subst | 1977 |
Blockade of morphine-withdrawal body shakes by haloperidol.
Topics: Animals; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Morphine; Rats; Substance With | 1976 |
Suppression of ethanol withdrawal by dopamine.
Topics: Animals; Dopamine; Ethanol; Haloperidol; Humans; Levodopa; Mice; Seizures; Substance Withdrawal Synd | 1976 |
Effect of pharmacological interference with various neuropathways on blockade of morphine-withdrawal hypothermia by morphine and by conditional stimulus.
Topics: Animals; Benztropine; Conditioning, Classical; Cyproheptadine; Haloperidol; Humans; Hypothermia; Mal | 1976 |
Enhancement of alcohol withdrawal convulsions in mice by haloperidol.
Topics: Animals; Chlordiazepoxide; Ethanol; Haloperidol; Humans; Mice; Seizures; Substance Withdrawal Syndro | 1976 |
Dopaminergic influence on withdrawal jumping behavior in morphine-dependent mice.
Topics: Animals; Apomorphine; Brain; Dopamine; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; | 1976 |
Narcotic withdrawal like mouse jumping produced by amphetamine and L-DOPA.
Topics: Amphetamine; Animals; Brain Chemistry; Dihydroxyphenylalanine; Dopamine; Fluorometry; Haloperidol; H | 1975 |
Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.
Topics: Animals; Apomorphine; Chlorpromazine; Clozapine; Corpus Striatum; Dibenzazepines; Dibenzoxazepines; | 1975 |
Tetrahydrocannabinol-attenuated abstinence and induced rotation in morphine-dependent rats: possible involvement of dopamine.
Topics: Animals; Behavior; Cannabis; Dopamine; Dronabinol; Haloperidol; Humans; Male; Morphine Dependence; N | 1975 |
Supersensitivity to dopaminergic agonists induced by haloperidol.
Topics: Animals; Apomorphine; Diet; Dopamine; Drug Interactions; Haloperidol; Humans; Male; Mice; Motor Acti | 1975 |
Activation of the zinc finger encoding gene krox-20 in adult rat brain: comparison with zif268.
Topics: Animals; Apomorphine; Benzazepines; Brain; DNA-Binding Proteins; Early Growth Response Protein 1; Ea | 1992 |
Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1992 |
Tolerance, withdrawal, and supersensitivity to dopamine mediated cues in a drug-drug discrimination.
Topics: Animals; Cues; Dextroamphetamine; Discrimination, Psychological; Dopamine; Drug Tolerance; Haloperid | 1992 |
Long-term influence of d-amphetamine on mesolimbic brain-stimulation reward: comparison to chronic haloperidol and naloxone effects.
Topics: Animals; Dextroamphetamine; Discrimination Learning; Electric Stimulation; Haloperidol; Limbic Syste | 1992 |
Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Topics: Administration, Oral; Adult; Brain; Dopamine; Fluphenazine; Haloperidol; Humans; Male; Prolactin; Ps | 1992 |
[Extrapyramidal movement disorders after "Isostar Cocktail"].
Topics: Adolescent; Basal Ganglia Diseases; Beverages; Biperiden; Dyskinesia, Drug-Induced; Food Contaminati | 1992 |
Haloperidol-induced dystonia and parkinsonism on discontinuing metoclopramide: implications for differential thalamocortical activity.
Topics: Adult; Brain; Drug Therapy, Combination; Dystonia; Female; Haloperidol; Humans; Metoclopramide; Park | 1992 |
CSF noradrenergic activity and sleep EEG in clinically stable schizophrenic patients after haloperidol withdrawal.
Topics: Adult; Dopamine beta-Hydroxylase; Electroencephalography; Haloperidol; Humans; Methoxyhydroxyphenylg | 1992 |
Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease.
Topics: Female; Haloperidol; Humans; Huntington Disease; Middle Aged; Neuroleptic Malignant Syndrome; Substa | 1992 |
Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients.
Topics: Adult; Delta Rhythm; Electroencephalography; Female; Haloperidol; Humans; Male; Middle Aged; Recurre | 1992 |
Neuroleptic withdrawal.
Topics: Antipsychotic Agents; Child; Child Behavior Disorders; Drug Therapy, Combination; Haloperidol; Human | 1991 |
Diltiazem suppresses quinpirole-induced oral stereotypies in haloperidol withdrawn rats.
Topics: Analysis of Variance; Animals; Diltiazem; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Halo | 1991 |
The influence of agonists and antagonists of dopaminergic system on the formation of audiogenic seizures in rats during the ethanol abstinence period.
Topics: Amantadine; Animals; Bromocriptine; Dopamine Agents; Dopamine Antagonists; Ethanol; Haloperidol; Mal | 1990 |
Neuroleptics in alcohol withdrawal.
Topics: Ethanol; Haloperidol; Humans; Substance Withdrawal Syndrome | 1992 |
[A case of neuroleptic malignant syndrome developed in liver cirrhosis patient addicted to alcohol].
Topics: Adult; Ethanol; Haloperidol; Humans; Liver Cirrhosis, Alcoholic; Male; Neuroleptic Malignant Syndrom | 1991 |
Dopaminergic activity and idiopathic edema.
Topics: Adult; Brain; Diuresis; Dopamine; Dyskinesia, Drug-Induced; Edema; Female; Galactorrhea; Haloperidol | 1991 |
Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study.
Topics: Acute Disease; Adult; Ambulatory Care; Clozapine; Haloperidol; Hospitalization; Humans; Male; Psychi | 1991 |
[Central anticholinergic intoxication syndrome. A contribution to the differential diagnosis of exogenous psychoses].
Topics: Akathisia, Drug-Induced; Biperiden; Diagnosis, Differential; Doxepin; Dysarthria; Dyskinesia, Drug-I | 1991 |
Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Drug Therapy, Co | 1990 |
Effect of haloperidol withdrawal on somatostatin level and binding in rat brain.
Topics: Animals; Binding, Competitive; Brain; Haloperidol; Male; Radioimmunoassay; Rats; Rats, Inbred Strain | 1990 |
Fluoxetine and neuroleptic synergistic effects.
Topics: Adolescent; Chlorpromazine; Diseases in Twins; Drug Synergism; Fluoxetine; Haloperidol; Humans; Male | 1991 |
Decreased striatal release of acetylcholine following withdrawal from long-term treatment with haloperidol: modulation by cholinergic, dopamine-D1 and -D2 mechanisms.
Topics: Acetylcholine; Animals; Benzazepines; Corpus Striatum; Haloperidol; In Vitro Techniques; Male; Paras | 1990 |
Tardive eating dystonia.
Topics: Aged; Aggression; Blepharospasm; Deglutition Disorders; Dyskinesia, Drug-Induced; Feeding and Eating | 1990 |
CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
Topics: Adult; Chromatography, High Pressure Liquid; Chronic Disease; Haloperidol; Homovanillic Acid; Humans | 1989 |
Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
Topics: Adult; Antipsychotic Agents; Brain; Chronic Disease; Dyskinesia, Drug-Induced; Electroencephalograph | 1989 |
Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
Topics: Adult; Antipsychotic Agents; Brain; Female; Fluphenazine; Haloperidol; Humans; Male; Prolactin; Psyc | 1989 |
Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; F | 1989 |
RBC and plasma choline in neuroleptic-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Brain; Choline; Chronic Disease; Erythrocytes; Female; Haloperidol; Hum | 1989 |
Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antipsychotic Agents; Chronic Disease; Dopamine; Female; Halo | 1985 |
Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine.
Topics: Aged; Amantadine; Dementia; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malign | 1989 |
Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Domperidone; Dopamine; Female; Flupenthixol; gamma-Ami | 1985 |
Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
Topics: Animals; Antipsychotic Agents; Benztropine; Cebus; Death, Sudden; Disease Models, Animal; Drug Thera | 1985 |
Prolonged pharmacologic activity of neuroleptics.
Topics: Animals; Antipsychotic Agents; Apomorphine; Dose-Response Relationship, Drug; Half-Life; Haloperidol | 1985 |
Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome.
Topics: Adrenergic beta-Antagonists; Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Benzodiazepines; Chl | 1986 |
The potentiation of morphine-withdrawal jumping by clonidine is antagonized by m-chlorophenylpiperazine and not by haloperidol.
Topics: Adrenergic alpha-Antagonists; Animals; Azepines; Behavior, Animal; Clonidine; Dopamine Antagonists; | 1986 |
Dopaminergic and alpha 1-adrenergic properties of B-HT920 revealed in morphine-dependent rats.
Topics: Adrenergic alpha-Agonists; Animals; Azepines; Dopamine; Haloperidol; Lisuride; Male; Morphine Depend | 1987 |
Tourette-like symptoms associated with neuroleptic therapy in an autistic child.
Topics: Autistic Disorder; Child, Preschool; Diagnosis, Differential; Dyskinesia, Drug-Induced; Haloperidol; | 1989 |
Enhancement by haloperidol of the locomotor response induced by naloxone in morphine-treated guinea pigs.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Guinea Pigs; Haloperidol; | 1989 |
Characteristics of oral movements in rats during and after chronic haloperidol and fluphenazine administration.
Topics: Animals; Female; Fluphenazine; Haloperidol; Mouth; Movement; Rats; Rats, Inbred Strains; Substance W | 1988 |
Hematemesis following discontinuation of psychoactive drugs in geriatric patients.
Topics: Aged; Chlorpromazine; Female; Haloperidol; Hematemesis; Humans; Imipramine; Male; Procyclidine; Psyc | 1988 |
Effects of ovariectomy and of estrogen administration on some dopamine-related behaviors in the rat.
Topics: Analysis of Variance; Animals; Apomorphine; Estradiol; Female; Haloperidol; Ovariectomy; Random Allo | 1988 |
Low-dose neuroleptic therapy for children with childhood-onset pervasive developmental disorder.
Topics: Behavior Therapy; Child; Child Development Disorders, Pervasive; Drug Administration Schedule; Femal | 1988 |
Withdrawal NMS after drug treatment.
Topics: Amitriptyline; Drug Therapy, Combination; Haloperidol; Humans; Imipramine; Neuroleptic Malignant Syn | 1988 |
Clonidine in the treatment of Tourette's syndrome exacerbation due to haloperidol withdrawal.
Topics: Acute Disease; Adult; Clonidine; Haloperidol; Humans; Male; Substance Withdrawal Syndrome; Tourette | 1986 |
Tardive dyskinesia following haloperidol treatment in Tourette's syndrome.
Topics: Adult; Age Factors; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Substance Withdrawal Syndro | 1987 |
Imidazole modification of aggressive behaviour in rats and mice.
Topics: Aggression; Animals; Haloperidol; Imidazoles; Lisuride; Male; Mice; Morphine Dependence; Rats; Rats, | 1987 |
[Effect of pharmacological substances on the altered permeability of the hemato-encephalic barrier for 14C-tyrosine due to ethanol].
Topics: Alcoholism; Animals; Blood-Brain Barrier; Carbon Radioisotopes; Cell Membrane Permeability; Chlorpro | 1987 |
Bromocriptine-related psychosis and treatment.
Topics: Adult; Bromocriptine; Female; Haloperidol; Humans; Pituitary Neoplasms; Prolactin; Psychoses, Substa | 1985 |
Persistent supersensitivity vomiting following neuroleptic withdrawal in an adolescent.
Topics: Adolescent; Haloperidol; Humans; Male; Substance Withdrawal Syndrome; Vomiting | 1986 |
Discriminative stimulus effects of morphine withdrawal in the dependent rat: suppression by opiate and nonopiate drugs.
Topics: Animals; Body Weight; Clonidine; Haloperidol; Humans; Male; Morphine Dependence; Naloxone; Naltrexon | 1985 |
Ontogeny of striatal unit activity and effects of single or repeated haloperidol administration in rats.
Topics: Animals; Animals, Newborn; Corpus Striatum; Dopamine; Electrophysiology; Haloperidol; Humans; Rats; | 1985 |
Effects of haloperidol on morphine-induced antinociception morphine tolerance and withdrawal in hyperprolactinaemic rats.
Topics: Animals; Drug Tolerance; Haloperidol; Male; Morphine; Naloxone; Nociceptors; Pituitary Gland, Anteri | 1985 |
Effects of phenoxybenzamine on the narcotic withdrawal syndrome in the rat.
Topics: Adrenergic beta-Antagonists; Animals; Behavior, Animal; Body Weight; Chlorpromazine; Depression, Che | 1974 |
[Sudden cessation of psychotropic drugs].
Topics: Adolescent; Adult; Amitriptyline; Antidepressive Agents; Bipolar Disorder; Blood Pressure; Chlorprom | 1974 |
Suppression of craving and other signs of dependence in morphine-addicted monkeys by administration of alpha-methyl-para-tyrosine.
Topics: Animals; Female; Fenclonine; Haloperidol; Haplorhini; Humans; Hypothalamus; Injections, Intravenous; | 1972 |
Serum cortisol in chronic schizophrenia. Changes in the response to intravenously administered insulin and ACTH on withdrawal of drugs.
Topics: Adrenocorticotropic Hormone; Aged; Amitriptyline; Blood Glucose; Chronic Disease; Female; Haloperido | 1971 |
The organic brain syndrome.
Topics: Alcoholic Intoxication; Attention; Chlordiazepoxide; Delirium; Haloperidol; Humans; Hydrocephalus; M | 1974 |
Chlorpromazine therapy, and associated acute disturbances of cardiac rhythm.
Topics: Adult; Blood Glucose; Chlorpromazine; Electrocardiography; Female; Haloperidol; Heart Block; Humans; | 1974 |
[Intense pentazocine abstinence syndrome. Treatment of a clinical case].
Topics: Administration, Oral; Adult; Butyrophenones; Diazepam; Drug Evaluation; Female; Haloperidol; Humans; | 1974 |
Non-addictive drug antagonist program in a community setting.
Topics: Adolescent; Adult; Age Factors; Allied Health Personnel; Ambulatory Care; Community Health Services; | 1973 |
Letter: Withdrawal syndrome after neuroleptics.
Topics: Adult; Chlorpromazine; Haloperidol; Humans; Male; Parkinson Disease, Secondary; Substance Withdrawal | 1973 |
Letter: Haloperidol in the treatment of stutterers.
Topics: Depression; Ethanol; Haloperidol; Humans; Piperazines; Sleep; Stuttering; Substance Withdrawal Syndr | 1973 |
Effect of dopaminergic stimulation or blockade on morphine-withdrawal aggression.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Dihydroxyphenylalanine; Haloperidol; Humans; Male; Me | 1973 |
Letter: Withdrawal symptoms after stopping phenelzine?
Topics: Adult; Depression; Female; Haloperidol; Headache; Humans; Male; Phenelzine; Shivering; Substance Wit | 1974 |
Tardive and withdrawal dyskinesia associated with haloperidol.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Butyrophenones; Dose-Response Relationship, Drug; Female; | 1974 |
Morphine physical dependence in the dog.
Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Dogs; Dose-Response Relationship, Drug; Ha | 1974 |
The effect of sedatives on the metabolic rate during alcohol withdrawal.
Topics: Adult; Alcoholism; Amobarbital; Basal Metabolism; Chlormethiazole; Chlorpromazine; Depression, Chemi | 1972 |
Serum cortisol in chronic schizophrenia. Changes in the diurnal rhythm and psychiatric mental status on withdrawal of drugs.
Topics: Aged; Amitriptyline; Chronic Disease; Circadian Rhythm; Cognition; Female; Haloperidol; Humans; Hydr | 1971 |
The treatment of acute alcohol intoxication and withdrawal.
Topics: Acute Disease; Adult; Alcoholic Intoxication; Alcoholism; Chlordiazepoxide; Chlormethiazole; Ethanol | 1970 |